Black Diamond reports Phase 2 silevertinib mPFS 15.2 months in frontline EGFR-mutant NSCLC

• Black Diamond Therapeutics reported positive Phase 2 results for silevertinib in first-line non-small cell lung cancer patients with non-classical EGFR mutations, with the data scheduled for presentation at ASCO on May 30, 2026.
• The study showed durable tumor control across a broad range of these mutations, supporting use as a frontline targeted option in an underserved patient group.
• Activity in the central nervous system was a key feature, with findings indicating strong control of existing brain disease and no new brain metastases during follow-up.
• The safety profile was described as manageable with dose adjustments, with the regimen for the next-stage program set at a lower daily dose.
• The company plans to engage the FDA later in 2026 to discuss a pivotal development strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Diamond Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605211713PRIMZONEFULLFEED9725062) on May 21, 2026, and is solely responsible for the information contained therein.